Core Viewpoint - The article highlights the significant IPO of Medline, a major player in the medical supplies industry, which has been closely watched by the private equity (PE) sector as a key indicator of the health of the IPO market since mid-2025 [5][6]. Group 1: Medline's IPO and PE Returns - Medline's IPO on December 18 saw a first-day surge of 41%, reaching a market capitalization of $54 billion (approximately 380 billion RMB), marking the largest IPO in the U.S. since 2025 and the largest in the healthcare sector in 14 years [5]. - The IPO is expected to yield significant returns for the PE consortium of Blackstone, Carlyle, and H&F, with potential earnings exceeding $17 billion (approximately 110 billion RMB) over four years, effectively doubling their equity capital investment [6]. - The IPO performance is viewed as a long-awaited success for the PE industry, which has faced a prolonged period of low activity [6]. Group 2: Medline's Historical Context and Business Model - Medline, founded in 1911, transitioned from a textile company to a leading medical supplies manufacturer, achieving annual sales exceeding $17 billion [8][11]. - The company has maintained a family-owned structure for decades, resisting external capital until the recent IPO, which was driven by family members seeking to capitalize on their substantial paper wealth [10][9]. - Medline's business model emphasizes vertical integration, controlling its own product brands, manufacturing, distribution, and logistics, which has allowed it to maintain higher profit margins and rapid response to market demands [22]. Group 3: Financial Performance and Market Position - Medline's revenue has shown consistent growth, with a reported $17.5 billion in 2020 and projected revenues of $25.5 billion for 2024, alongside an increase in EBITDA from approximately $2 billion to $3.4 billion [23]. - The company has a remarkable customer retention rate of 98%, attributed to its unique customer experience and the essential nature of its products [23]. - Medline's strategic investments in infrastructure and supply chain resilience have positioned it as a stable supplier during the pandemic, enhancing its market share in the U.S. healthcare sector [23]. Group 4: PE Acquisition and Market Dynamics - The acquisition of Medline in 2021 for $34 billion was notable for its equal investment from the three PE firms, reflecting a competitive bidding environment among top financial institutions [13][18]. - The timing of the acquisition coincided with a peak in market conditions, raising concerns about potential overvaluation, as the purchase price was approximately 15-16 times EBITDA, compared to a typical valuation of 10 times for similar companies [16]. - Despite the subsequent downturn in the capital markets, Medline's valuation has continued to grow, demonstrating the resilience of high-quality companies in varying market conditions [25].

Core Viewpoint - The article highlights the significant IPO of Medline, marking a major success for the PE industry after a prolonged period of IPO stagnation, with Medline's market capitalization reaching $54 billion on its debut [3][4]. Group 1: Medline's IPO and PE Industry Impact - Medline's IPO on December 18, 2025, saw a first-day surge of 41%, establishing it as the largest IPO in the U.S. since 2025 and the largest in the healthcare sector in nearly 14 years [3]. - The IPO is viewed as a critical test for the recent "IPO wave" in the U.S. stock market, with the potential to set a new record for PE-backed IPOs [4]. - The three PE firms involved in Medline's acquisition—Blackstone, Carlyle, and H&F—are expected to achieve returns of approximately two times their equity capital, netting over $17 billion (approximately 110 billion RMB) in profits [4]. Group 2: Medline's Historical Context and Business Model - Medline, a century-old family business, transitioned from a textile manufacturer to a leading medical supplies company, generating over $17 billion in annual sales [6][8]. - The company historically resisted external capital, opting for a family-owned model until the need for re-capitalization arose due to the family's inability to access their wealth [7][6]. - Medline's business model emphasizes vertical integration, controlling its own brands, manufacturing, distribution, and logistics, which has allowed it to maintain superior margins and rapid response to market demands [17]. Group 3: Financial Performance and Market Position - Medline's revenue grew from $17.5 billion in 2020 to $25.5 billion in 2024, with EBITDA increasing from an estimated $2 billion to $3.4 billion during the same period [18]. - The company boasts a customer retention rate of 98%, indicating strong demand stability for its products, which are essential in the healthcare sector [18]. - Despite market challenges, Medline's valuation has continued to rise, demonstrating the resilience of high-quality companies in various market conditions [19].